Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation

被引：14

作者：

Walsh, Shawn P. ^{[1
]}

Shahripour, Aurash ^{[1
]}

Tang, Haifeng ^{[1
]}

Teumelsan, Nardos ^{[1
]}

Frie, Jessica ^{[1
]}

Zhu, Yuping ^{[1
]}

Priest, Birgit T. ^{[2
]}

Swensen, Andrew M. ^{[2
]}

Liu, Jessica ^{[2
]}

Margulis, Michael ^{[2
]}

Visconti, Richard ^{[2
]}

Weinglass, Adam ^{[2
]}

Felix, John P. ^{[2
]}

Brochu, Richard M. ^{[2
]}

Bailey, Timothy ^{[2
]}

Thomas-Fowlkes, Brande ^{[2
]}

Alonso-Galicia, Magdalena ^{[3
]}

Zhou, Xiaoyan ^{[3
]}

Pai, Lee-Yuh ^{[3
]}

Corona, Aaron ^{[3
]}

Hampton, Caryn ^{[3
]}

Hernandez, Melba ^{[3
]}

Bentley, Ross ^{[3
]}

Chen, Jing ^{[3
]}

Shah, Kashmira ^{[3
]}

Metzger, Joseph ^{[3
]}

Forrest, Michael ^{[3
]}

Owens, Karen ^{[4
]}

Tong, Vincent ^{[4
]}

Ha, Sookhee ^{[5
]}

Roy, Sophie ^{[3
]}

Kaczorowski, Gregory J. ^{[2
]}

Yang, Lihu ^{[1
]}

Parmee, Emma ^{[1
]}

Garcia, Maria L. ^{[2
]}

Sullivan, Kathleen ^{[3
]}

Pasternak, Alexander ^{[1
]}

机构：

[1] Merck Res Labs, Discovery Chem, Kenilworth, NJ 07033 USA

[2] Merck Res Labs, Dept Pharmacol, Kenilworth, NJ 07033 USA

[3] Merck Res Labs, Dept Cardiometab Dis, Kenilworth, NJ 07033 USA

[4] Merck Res Labs, Pharmacokinet Pharmacodynam & Drug Metab, Kenilworth, NJ 07033 USA

[5] Merck Res Labs, Dept Chem Modeling & Informat, Kenilworth, NJ 07033 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2015年 / 6卷 / 07期

关键词：

ROMK; hypertension; heart failure; diuresis; natriuresis; POTASSIUM CHANNEL; BLOOD-PRESSURE; DIURETICS; CLONING; KIR1.1;

D O I：

10.1021/ml500440u

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A new subseries of ROMK inhibitors exemplified by 28 has been developed from the initial screening hit 1. The excellent selectivity for ROMK inhibition over related ion channels and pharmacokinetic properties across preclinical species support further preclinical evaluation of 28 as a new mechanism diuretic. Robust pharmacodynamic effects in both SD rats and dogs have been demonstrated.

引用

页码：747 / 752

页数：6

共 50 条

[21] Preclinical evaluation of HM-018, a potent and selective JAK inhibitor in the treatment of myloproliferative disorders
Ren, Yongxin
Deng, Wei
Gu, Weihua
Shen, Wuzhong
Yu, Youjun
Yang, Xiaoning
Zhang, Zhixiang
Fan, Shiming
Sai, Yang
Wang, Jian
Yan, James
Li, Jia
Zhao, Helen
Qing, Weiguo
Su, Weiguo
CANCER RESEARCH, 2012, 72
[22] Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization
Nilsson, Magnus
Berggren, Kristina
Berglund, Susanne
Cerboni, Silvia
Collins, Mia
Dahl, Goran
Elmqvist, David
Grimster, Neil P.
Hendrickx, Ramon
Johansson, Johan R.
Kettle, Jason G.
Lepisto, Matti
Rhedin, Magdalena
Smailagic, Amir
Su, Qibin
Wennberg, Tiiu
Wu, Allan
Osterlund, Torben
Naessens, Thomas
Mitra, Suman
JOURNAL OF MEDICINAL CHEMISTRY, 2023, : 13400 - 13415
[23] Discovery and SAR evolution of potent and selective ROMK inhibitors: Strategies for improved selectivity over the hERG channel
Walsh, Shawn
Kim, Esther
Shahripour, Aurash
Tang, Haifeng
DeJesus, Reynalda
Zhu, Yuping
Teumelson, Nardos
Frie, Jessica
Yang, Lihu
Parmee, Emma
Priest, Birgit
Thomas-Fowlke, Brande
Swenson, Andrew
Kaczorowski, Gregory
Garcia, Maria
Weinglass, Adam
Alonso-Galicia, Magdelana
Zhou, Xiaoyan
Pai, Lee-Yuh
Hampton, Caryn
Kunkel, Jodie
Price, Olga
Hernandez, Melba
Gill, Charlie
Dajee, Maya
Shah, Kashmira
Metzger, Joseph
Forrest, Micheal
Ormes, James
Hu, Mengwei
Owens, Karen
Samuel, Koppora
Miller, Randy
Tong, Vincent
Bateman, Thomas
Roy, Sophie
Sullivan, Kathleen
Pasternak, Alexander
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[24] Preclinical and clinical properties of trimegestone: A potent and selective progestin
Sitruk-Ware, Regine
Bossemeyer, Ronald
Bouchard, Phillipe
GYNECOLOGICAL ENDOCRINOLOGY, 2007, 23 (06) : 310 - 319
[25] Preclinical evaluation of GST-HG161, a potent and highly selective c-MET inhibitor
Xu, Xiongbin
Li, Gang
Hu, Lihong
Hao, Junguo
Ding, Charles Z.
Chen, Shuhui
CANCER RESEARCH, 2018, 78 (13)
[26] Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study
Bekker, Pirow
Dairaghi, Daniel
Seitz, Lisa
Leleti, Manmohan
Wang, Yu
Ertl, Linda
Baumgart, Trageen
Shugarts, Sarah
Lohr, Lisa
Dang, Ton
Miao, Shichang
Zeng, Yibin
Fan, Pingchen
Zhang, Penglie
Johnson, Daniel
Powers, Jay
Jaen, Juan
Charo, Israel
Schall, Thomas J.
PLOS ONE, 2016, 11 (10):
[27] Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
He, Kan
Luettgen, Joseph M.
Zhang, Donglu
He, Bing
Grace, James E., Jr.
Xin, Baomin
Pinto, Donald J. P.
Wong, Pancras C.
Knabb, Robert M.
Lam, Patrick Y. S.
Wexler, Ruth R.
Grossman, Scott J.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2011, 36 (03) : 129 - 139
[28] Discovery of a potent and selective small molecule inhibitor of PKD functionality
Wang, Q.
Sharlow, Elizabeth
Giridhar, Karthik
LaValle, Courtney
Chen, Jun
Leimgruber, Stephanie
Barrett, Rebecca
Bravo-Altamirano, Karla
Wipf, Peter
Lazo, John
CANCER RESEARCH, 2009, 69
[29] The Discovery of Setileuton, a Potent and Selective 5-Lipoxygenase Inhibitor
Ducharme, Yves
Blouin, Marc
Brideau, Christine
Chateauneuf, Anne
Gareau, Yves
Grimm, Erich L.
Juteau, Helene
Laliberte, Sebastien
MacKay, Bruce
Masse, Frederic
Ouellet, Marc
Salem, Myriam
Styhler, Angela
Friesen, Richard W.
ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (04): : 170 - 174
[30] The discovery and preclinical evaluation of BMS-707035, a potent HIV-1 integrase strand transfer inhibitor
Naidu, B. Narasimhulu
Walker, Michael A.
Sorenson, Margaret E.
Ueda, Yasutsugu
Matiskella, John D.
Connolly, Timothy P.
Dicker, Ira B.
Lin, Zeyu
Bollini, Sagarika
Terry, Brian J.
Higley, Helen
Zheng, Ming
Parker, Dawn D.
Wu, Dedong
Adams, Stephen
Krystal, Mark R.
Meanwell, Nicholas A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (12) : 2124 - 2130

← 1 2 3 4 5 →